Clinical News-CliniExpert

ViaCyte's Stem Cell-Derived Treatment for Type 1 Diabetes Shows Promising Results in Two Published Studies

SAN DIEGO, Dec. 2, 2021 -- ViaCyte, Inc., a clinical-stage regenerative medicine company focused on developing novel cell replacement therapies to address diseases with significant unmet needs, announ

Novavax Statement on Omicron Variant Response

December 2, 2021 -- Novavax is rapidly responding to the emergence of the latest potential threat of the SARS-CoV-2 Omicron (B.1.1.529) variant of concern (VoC). The company is executing a two-pronged

Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant

Preclinical data demonstrate sotrovimab, authorised in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron Data to be confi

Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD

CAMBRIDGE, Mass. – December 1, 2021 -- Sage Therapeutics, Inc. (Nasdaq: SAGE), and Biogen Inc. (Nasdaq: BIIB) today announced 12-month data for the cohort of patients (n=199), who received zuranolone

Insightec Announces FDA Clearance For Exablate Prostate To Treat Prostate Tissue

HAIFA, Israel and MIAMI, Fla., Dec. 1, 2021 -- Insightec, a global healthcare company creating the next generation of patient care by realizing the therapeutic power of acoustic energy, announced toda

SK Bioscience and GSK Start Phase 3 trial of Adjuvanted COVID-19 Vaccine Candidate

Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data Global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine Aim is for glob

Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia

PARSIPPANY, N.J., TEL AVIV & PARIS--(BUSINESS WIRE) August 31, 2021 -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and MedinCell (Euronext:

Bayer Starts Phase III Clinical Development Program OASIS With Investigational Product, Elinzanetant

Elinzanetant is a non-hormonal development compound investigated for the treatment of vasomotor symptoms during menopause WHIPPANY, N.J.--(BUSINESS WIRE) August 31, 2021-- Bayer, a global leader in wo

Novavax Statement on CDC Guidance Update for COVID-19 Clinical Trial Participants

GAITHERSBURG, Md., Aug. 30, 2021 -- Novavax, Inc. , a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Centers for Disease Contr

Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis

NEW YORK--(BUSINESS WIRE) August 30, 2021 -- Pfizer Inc. (NYSE: PFE) today announced that JADE DARE (B7451050), a 26-week, randomized, double-blind, double-dummy, active-controlled, multi-center Phase

Study Data Show Abbott's CardioMEMSDevice Can Improve Care for More Patients with Heart Failure

ABBOTT PARK, Ill., Aug. 27, 2021 -- Abbott today announced results of the landmark GUIDE-HF clinical trial, a 1,000 patient randomized study designed to assess the benefits of the CardioMEMS HF System

Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Severe COVID-19 Patients

CINCINNATI, Aug. 26, 2021 -- Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respira